Moody's: FDA Approval of Generic Nilandron is Credit Negative for Concordia; no change to rating or outlook

20. Juli 2016 INDIZES USA

New York, July 20, 2016 — Moody’s Investors Service commented that the FDA approval of ANI Pharmaceuticals’ (not rated …
(Orginal – Story lesen…)